Quantcast

Industry news that matters to you.  Learn more

Life Technologies and Advanced Cell Diagnostics Sign Global Distribution Agreement

Life Technologies Corporation (NASDAQ: LIFE) and Advanced Cell Diagnostics, Inc. (ACD), a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, recently announced a global distribution agreement by which Life will distribute ACD’s fluorescent RNAscope® portfolio of probes and kits to the research market through its worldwide distribution network.

Frost & Sullivan Honours PathXL with Enabling Technology Award

Based on its recent analysis of web-based software platforms for tissue analysis and quantification, Frost & Sullivan recognise PathXL (Northern Ireland) with the 2012 European Web-based Software Platforms Enabling Technology Award.

Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients

Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in cancer patients, and Clarient, Inc. (a GE Healthcare Company) today announced a collaboration on the commercialization of a proprietary blood test for CTCs in breast cancer patients, which includes the determination of HER2 status. Clarient and Biocept will market and sell Biocept’s new OncoCEE-BR CTC test to community hospitals, pathologists and medical oncologists. Biocept will perform the test in its laboratories, and results will be interpreted by Clarient’s highly respected pathology group (Clarient Pathology Services, Inc.). The test includes CTC enumeration and HER2 status of the detected CTCs by fluorescence in situ hybridization (FISH); it is the first commercially available CTC test to include analysis of a specific treatment-associated biomarker.

Expression Pathology Provides Roche Biomarker Assay Services for Oncology Drug Development

Expression Pathology recently announced an agreement with Roche to provide its Liquid Tissue-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.

Caliper Life Sciences to Aquire Cambridge Research & Instrumentation

Caliper Life Sciences has announced that it has entered into definitive agreement to aquire privately-held Cambridge Research & Instrumentation (CRi) for approximately $20.0 million.